AndreaBozzo/ceres-open-data-index huggingface dataset:
Analysis of immunoglobulin light chain rearrangements in the salivary gland and blood of a patient with Sjögren's syndrome

Patients with Sjögren's syndrome (SS) have characteristic lymphocytic infiltrates of the salivary glands. To determine whether the B cells accumulating in the salivary glands of SS patients represent a distinct population and to delineate their potential immunopathologic impact, individual B cells obtained from the parotid gland and from the peripheral blood were analyzed for immunglobulin light chain gene rearrangements by PCR amplification of genomic DNA. The productive immunglobulin light chain repertoire in the parotid gland of the SS patient was found to be restricted, showing a preferential usage of particular variable lambda chain genes (Vλ2E) and variable kappa chain genes (VκA27). Moreover, clonally related VL chain rearrangements were identified; namely, VκA27–Jκ5 and VκA19–Jκ2 in the parotid gland, and Vλ1C–Jλ3 in the parotid gland and the peripheral blood. Vκ and Vλ rearrangements from the parotid gland exhibited a significantly elevated mutational frequency compared with those from the peripheral blood (P < 0.001). Mutational analysis revealed a pattern of somatic hypermutation similar to that found in normal donors, and a comparable impact of selection of mutated rearrangements in both the peripheral blood and the parotid gland. These data indicate that there is biased usage of VL chain genes caused by selection and clonal expansion of B cells expressing particular VL genes. In addition, the data document an accumulation of B cells bearing mutated VL gene rearrangements within the parotid gland of the SS patient. These results suggest a role of antigen-activated and selected B cells in the local autoimmune process in SS.
What can we do about osteoarthritis?

Osteoarthritis is complex in genetics, pathogenesis, monitoring and treatment. Current treatment of osteoarthritis does not influence progression. Much could be gained by more effective 'low-tech-low-cost' treatment. However, many patients have rapidly progressive disease, multiple joint involvement, and severe disease. We need to clarify the genetics of osteoarthritis, identify those at risk for progression and severe disease, and identify molecular processes critical for joint survival and failure. Will saving the cartilage improve patient pain and function? Effective outcome measures are needed to accelerate testing of new treatments. Further improvement is needed in joint implant technology to decrease costs, wear and loosening.
Chicago-Joliet-Naperville, IL-IN-WI

This report presents combined 2005 to 2010 National Survey on Drug Use and Health (NSDUH) results for those aged 12 or older in the Chicago-Joliet-Naperville, IL-IN-WI metro area. The report includes estimates of substance use disorder, major depressive episode, illicit drug use, marijuana use, cigarette use, binge alcohol use, and the nonmedical use of prescription-type pain relievers. Results are provided for the Chicago-Joliet-Naperville metro area, Illinois, and the U.S. overall.
West (W)

This report presents the West\'s (e.g., combines Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming) estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for the West for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
4.18a Types of client payments accepted by facility, by facility operation and primary focus of facility: 2011. Number

This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing types of client payments accepted by facility, by facility operation and primary focus of facility in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.
Compound 526146: Trimethylsilyl 7-[3,5-bis(trimethylsilyloxy)-2-(3-trimethylsilyloxyoct-1-enyl)cyclopentyl]hept-5-enoate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 7-[3,5-bis(trimethylsilyloxy)-2-(3-trimethylsilyloxyoct-1-enyl)cyclopentyl]hept-5-enoate. Molecular Formula: C32H66O5Si4. Molecular Weight: 643.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525696: p-Methoxybenzylidene-(3-methoxyphenyl)-amine

Chemical compound data from PubChem database. IUPAC Name: N-(3-methoxyphenyl)-1-(4-methoxyphenyl)methanimine. Molecular Formula: C15H15NO2. Molecular Weight: 241.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists

Interleukin-4 (IL-4) mediates important pro-inflammatory functions in asthma including induction of the IgE isotype switch, expression of vascular cell adhesion molecule-1 (VCAM-1), promotion of eosinophil transmigration across endothelium, mucus secretion, and differentiation of T helper type 2 lymphocytes leading to cytokine release. Asthma is a complex genetic disorder that has been linked to polymorphisms in the IL-4 gene promoter and proteins involved in IL-4 signaling. Soluble recombinant IL-4 receptor lacks transmembrane and cytoplasmic activating domains and can therefore sequester IL-4 without mediating cellular activation. We report the results of initial clinical trials, which demonstrate clinical efficacy of this naturally occurring IL-4 antagonist as a therapeutic agent in asthma.
Compound 525915: 6-Methyl-3-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptan-2-one

Chemical compound data from PubChem database. IUPAC Name: 6-methyl-3-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptan-2-one. Molecular Formula: C10H14O2. Molecular Weight: 166.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hospital Inpatient Discharges (SPARCS De-Identified): Patient Safety Indicators (PSI) by Hospital: Beginning 2009

The datasets contain hospital discharges counts (numerators, denominators, volume counts), observed, expected and risk-adjusted rates with corresponding 95% confidence intervals for Patient Safety Indicators generated using methodology developed by Agency for Healthcare Research and Quality (AHRQ).

The PSIs are a set of indicators providing information on potential in hospital complications and adverse events following surgeries, procedures, and childbirth. The PSIs were developed by AHRQ after a comprehensive literature review, analysis of ICD-9-CM codes, review by a clinician panel, implementation of risk adjustment, and empirical analyses.

All PSI measures were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data beginning 2009.  US Census data files provided by AHRQ were used to derive denominators for county level (area level) PSI measures.

The mortality, volume and utilization measures PSIs are presented by hospital as rates or counts. Area-level measures are presented by county as rates.
Is primary care ready to take on Attention Deficit Hyperactivity Disorder?

Background
          Attention Deficit Hyperactivity Disorder (ADHD) is a common childhood psychiatric disorder. The management of ADHD has recently been highlighted. The National Institute of Clinical Excellence (NICE) and Scottish Intercollegiate Guidelines network (SIGN) have both produced management guidelines. Doctors working within Primary Care in countries such as the United States play an important role in the management of ADHD. In the United Kingdom however the role of doctors in primary care in the management of ADHD, both individually and within shared care protocols, is only now being identified and defined. Is this role for Primary Care likely to be acceptable and effective?
        
        
          Discussion
          There is some evidence that doctors working within Primary Care in the United Kingdom are willing to follow up children on medication for ADHD and carry out monitoring of physical status. However many feel unconfident in the management of ADHD and most have received little or no training in child psychiatry. There are also concerns that adverse media reports will have an undue influence on the attitudes of doctors within primary care to families with children suffering from ADHD.
        
        
          Summary
          There are important barriers to be tackled before shared care protocols for ADHD can be successfully implemented in the United Kingdom. Tailored information about ADHD needs to be provided to doctors in primary care. Clear dialogue between planners and healthcare professionals from both primary and secondary care is essential to ensure that service delivery is acceptable to healthcare providers, tailored to their skills and is adequately resourced.
Ziconotide acetate

Prialt (ziconotide acetate) is a prescription injectable medication, administered intrathecally (into the spinal canal), used to treat severe chronic pain in adults. It works by blocking certain calcium channels in the nervous system. Manufactured by TerSera Therapeutics LLC, it comes in various strengths like 100 mcg/mL. This information was generated using AI and is provided for informational and research purposes only.
RxClass

The RxClass Browser is a web application for exploring and navigating through the class hierarchies to find the RxNorm drug members associated with each class.

RxClass links drug classes of several drug sources including ATC, MeSH, NDF-RT and FDA/SPL to their RxNorm drug members (ingredients, precise ingredients and multiple ingredients).

RxClass allows users to search by class name or identifier to find the RxNorm drug members or, conversely, search by RxNorm drug name or identifier to find the classes that the RxNorm drug is a member of.
Compound 528315: Pyrazine, 3-ethoxy-2-pentyl

Chemical compound data from PubChem database. IUPAC Name: 2-ethoxy-3-pentylpyrazine. Molecular Formula: C11H18N2O. Molecular Weight: 194.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525246: N''-(4-chloro-phenyl)-N,N,N',N'-tetramethyl-guanidine

Chemical compound data from PubChem database. IUPAC Name: 2-(4-chlorophenyl)-1,1,3,3-tetramethylguanidine. Molecular Formula: C11H16ClN3. Molecular Weight: 225.72. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Publications Using SAMHSA DataNorth Dakota 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Vaccine Preventable Disease Cases by County and Year

These data contain counts of vaccine preventable disease cases among California residents by county, disease, and year.

The California Department of Public Health (CDPH) maintains a mandatory, passive reporting system for a list(1) of communicable disease cases and outbreaks. The CDPH Immunization Branch conducts surveillance for vaccine preventable diseases. Health care providers and laboratories are mandated to report cases or suspected cases of these communicable diseases to their local health department (LHD). LHDs are also mandated to report these cases to CDPH.

## Materials and Methods 

### Case data sources and inclusion criteria 

Data were extracted on communicable disease cases with an estimated onset or diagnosis date from 2001 through the last year indicated, from California Confidential Morbidity Reports and/or Laboratory Reports that were submitted to CDPH and which met the surveillance case definition for that disease.(2) Because of inherent delays in case reporting and depending on the length of follow-up of clinical, laboratory and epidemiologic investigation, cases with eligible onset dates may be added or rescinded after the date of this report. 

### Definitions 

In general, we defined a case as laboratory and/or clinical evidence of infection or disease in a person that satisfied the communicable disease surveillance case definition published by the United States (US) Centers for Disease Control and Prevention (CDC) or by the Council of State and Territorial Epidemiologists (CSTE) at the time the case was reported. 

## Limitations 

### Completeness of reporting 

The numbers of disease cases in this report are likely to underestimate the true magnitude of disease. Among factors that may contribute to under-reporting are: delays in notification, limited collection or appropriate testing of specimens, health care seeking behavior among ill persons, limited resources and competing priorities in LHDs, and lack of reporting by clinicians and laboratories. Among factors that may contribute to changes in reporting are disease severity, the availability of new or less expensive diagnostic tests, changes in the case definition by CDC or CDPH, changes in mandatory reporting requirements, recent media or public attention, and active surveillance activities. Differential reporting practices among LHDs may also result in inconsistent reporting of patient information.

### References 

1. California Code of Regulations, Title 17, Sections 2500 and 2505 
https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/ReportableDiseases.pdf 

2. Center for Disease Control and Prevention, National Notifiable Diseases Surveillance System https://ndc.services.cdc.gov/
Patent AT-E400229-T1: [Translated] BONE FIXATION SYSTEM

Clamping devices (61) attach to longitudinal drilled holes (35) in femur marrow nails (11) and adjust on-axis in the hole in relation to the nails. Adjusting movement in the clamping devices firmly clamps screws (15) passed through transverse drilled holes in the nails between the clamping devices and the inner walls of the nails bordering the transverse drilled holes.
Compound 526516: [10,13-dimethyl-17-(6-methylheptan-2-yl)-3-trimethylsilyloxy-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-7-yl]oxy-trimethylsilane

Chemical compound data from PubChem database. IUPAC Name: [10,13-dimethyl-17-(6-methylheptan-2-yl)-3-trimethylsilyloxy-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-7-yl]oxy-trimethylsilane. Molecular Formula: C33H62O2Si2. Molecular Weight: 547.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Survey of Substance Abuse Treatment Services: State Profiles 2016

The 2016 National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. The N-SSATS, conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), is designed to collect data on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse facilities (both public and private) throughout the 50 states, the District of Columbia, and other U.S. jurisdictions.
Elevated serum immunoglobulin E to

Background
          The possible participation of diesel exhaust inhalation during the fetal period in the elevation of IgE against pollen in postnatal life was investigated.
        
        
          Method
          The experiment was conducted using rat pups. Group I; exposed to clean air (Control). Group 2, 3; exposed to total or filtered diesel exhaust during the fetal period (Total-C-C, Filtered-C-C). Group 4, 5; exposed to total or filtered diesel exhaust during the suckling period (C-Total-C, C-Filtered-C). Group 6,7; exposed to total or filtered diesel exhaust during the weaning period (C-C-Total, C-C-Filtered). Total diesel engine exhaust contained 1.73 mg/m3 particulate matter and 0.79 ppm nitrogen dioxide; filtered exhaust contained the same gases as the total exhaust without particulate matter. Intraperitoneal injection of 5 mg crude cedar pollen was performed at 2-week intervals from the 49th day after birth.
        
        
          Results
          The mean IgE titers measured by the P-K reaction in the Control, Total-C-C, Filtered-C-C, C-Total-C, C-Filtered-C, C-C-Total and C-C-Filtered were 64.0 ± 2.7, 469.5 ± 1.6, 332.0 ± 1.7, 380.4 ± 1.7, 394.8 ± 1.7, 115.9 ± 1.3 and 57.0 ± 2.8 respectively after the fourth immunization. There were significant differences between Total-C-C, Filtered-C-C, C-Total-C, C-Filtered-C and Control (p < 0.01, p < 0.01, p < 0.05, p < 0.01, respectively). The mean IgE titers by ELISA were 0.47 ± 0.06, 0.79 ± 0.35, 0.86 ± 0.46, 0.80 ± 0.22, 0.56 ± 0.08, 0.46 ± 0.04 and 0.45 ± 0.03, respectively. IgE titers in Filtered-C-C and C-Total-C were significantly higher than in Control (p < 0.05 for each).
        
        
          Conclusions
          Inhalation of diesel exhaust during differentiation of the immune system accelerated the elevation of IgE against pollen.
Patent AT-E401253-T1: [Translated] SYNTHETIC BOTTLE CAP

Chemical patent from PubChem database. Patent Number: AT-E401253-T1. Title: Pharmaceutical Salt Forms. Filing Date: 1996-11-06. Inventors: Chen, Wei, Kumar, Raj, Williams, Sarah. Abstract: Novel pharmaceutical salt forms are provided, exhibiting improved physicochemical properties including enhanced solubility, stability, and bioavailabi... IPC Classifications: C07D, C07F, A61K. This patent covers 46 claims related to 2 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 525474: 4,7-Dithia-1,9-decadiene

Chemical compound data from PubChem database. IUPAC Name: 3-(2-prop-2-enylsulfanylethylsulfanyl)prop-1-ene. Molecular Formula: C8H14S2. Molecular Weight: 174.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Emergency Department Visits Involving Underage Alcohol Misuse: 2010 to 2013

This short report uses data from the AHRQ Healthcare Cost and Utilization Project Nationwide Emergency Department Sample (HCUP-NEDS) to assess the  prevalence of underage alcohol misuse–related emergency department (ED) visits.  Changes in the trends of alcohol-only and drug and alcohol-combination ED visits by age, gender and time are examined.
COVID-19 State Profile Report - Tennessee

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Patent AT-E401663-T1: [Translated] ELECTRICAL CIRCUIT FOR A SELF-LOCKING RELAY

An electrical relay circuit, comprising a load circuit with a series connection of a first generator (G1), a load component (R load) and a relay switch (S1) of a relay (RL1), wherein the relay switch (S1) has a closed position in which the load circuit is closed, and wherein the relay switch (S1) hat a magnetized position in which the load circuit is broken, further comprising an auxiliary circuit with a second generator (G2) for providing a control signal, wherein by means of the control signal the relay switch (S1) can be switched into the magnetised position, and wherein the auxiliary circuit keeps the relay switch (S1) in the magnetized position after the control signal is over, is characterized in that the first generator (G1) is connected to a series connection of the relay (RL1) and a constant current source (CCS) in both positions of the relay switch (S1), that the constant current source (CCS) is connected to an activation circuit (A) comprising the second generator (G2), wherein the constant current source (CCS) can be put into the activated state by the activation circuit (A) when the relay switch (S1) is in the closed position, and that the constant current source (CCS) is further connected to a holding circuit (H), wherein the holding circuit (H) keeps the constant current source (CCS) in the activated state when the relay switch (S1) is in the magnetised position. This simple, self-retaining relay circuit may be operated in a wide range of voltages.